跳至主要内容
临床试验/RBR-3wshg2m
RBR-3wshg2m招募中4 期

Analysis of humoral and cellular immune responses to 13-valent pneumococcal conjugate vaccine and 23-valent polysaccharide vaccine in patients living with HIV/AIDS

Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo0 个研究点开始时间: 2023年6月29日最近更新:

试验速览

阶段
4 期
状态
招募中
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Intervention

入排标准

年龄范围
18Y 至 0(—)

入选标准

  • HIV-infected patients confirmed by confirmatory tests (Western-Blott and/or HIV polymerase chain reaction viral load) who are of any gender identity. Being in regular use of highly effective antiretroviral, according to the definitions of the Ministry of Health, for at least four weeks. Minimum age 18 years old. Signature of the Free and Informed Consent Form (Appendix A) . For the control group: negative quick test for HIV

排除标准

  • Patient with a history of anaphylactic reaction to pneumococcal conjugate vaccines (PCV-7, PCV-10 or PCV-13) or 23-valent pneumococcal polysaccharide vacines. Previous vaccination with PCV-7, PCV-10, PCV-13 (interference in the evaluation of the pre-vaccination humoral immune response). Have been vaccinated with PPV-23 less than 1 year ago. Transfusion of blood components or Immunoglobulins in the last 28 days before vaccination with PCV-13 or PPV-23. Blood dyscrasias that prevent intramuscular vaccine application; Fever in the last 24 hours before vaccination

研究者

发起方
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo

相似试验